吃瓜不打烊

Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
    All Public Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Healthcare Helpline
    • 吃瓜不打烊 Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • Common Ground
    • Diagnosis: Debt
    • The Body Shops
    • Priced Out
    • Guns, Race, and Profit
    • Broken Rehab
    • Dead Zone
    • Denied
    • Opioid Settlement Tracking
    • Eleven Minutes
    All Special Reports
  • More Topics

    More Topics

    • Elections
    • Healthcare Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health
    All Topics

  • Medicare Advantage Billing Probe
  • School Vaccine Mandates
  • Weight Loss Drugs Coverage
  • Opioid Settlement Money
  • Abortion Pill Access

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Wednesday, Aug 9 2017

Full Issue

N.H., 'Ground Zero' Of Opioid Epidemic, Sues OxyContin-Maker Over Its Marketing Tactics

Suing the companies that make the painkillers is a new trend in states' efforts to combat the crisis. The New Hampshire case comes less than two months after Missouri's attorney general sued Purdue and two other pharmaceutical companies. In other news, a study finds that abuse-deterrent opioids aren't effective and investors are flocking to a company that makes a medication that treats addiction.

The attorney general's office sued Purdue Pharma on Tuesday, alleging that the drug manufacturer has continued its deceptive marketing of OxyContin in a state that has been called the "ground zero" of the opioid epidemic. In a civil complaint, the state alleges that Purdue Pharma has downplayed the drug's risk of addiction, overstated its effectiveness, claimed it is nearly impossible to abuse and failed to report suspicious prescribers. It's the latest in a string of lawsuits by state, county and local governments accusing prescription opioid manufacturers of fraud and deceptive marketing. (8/8)

New Hampshire鈥檚 lawsuit against Purdue Pharma is being brought under the state鈥檚 consumer protection act. The head of that unit, Senior Assistant Attorney General Jim Boffetti, says investigators spoke with local doctors who claimed Purdue reps visited them as often as two or three times a week. The company, he says, downplayed the addictive risks of OxyContin and other opioids, particularly in patients being treated for chronic pain. (McDermott, 8/8)

The deputy chief of the U.S. Drug Enforcement Administration has called New Hampshire 鈥済round zero鈥 of the opioid epidemic and the Centers for Disease Control reports four of five heroin users started with prescription opioids. 鈥淭o defeat the epidemic, we must stop creating new users, and part of that is making sure these highly addictive and dangerous drugs are marketed truthfully and without deception and in such a way as not to minimize addiction risks or overstate benefits to patients,鈥 Rice said. (Landrigan, 8/8)

As the opioid crisis rages across the United States, a new analysis contends there is a lack of evidence that pills designed to deter abuse are truly effective in reducing overall opioid abuse and, moreover, the cost to prevent a single case of abuse or an overdose death may appear prohibitive. After reviewing available studies, a panel of experts concluded data to support most of the so-called abuse deterrent formulations is 鈥減romising, but inconclusive,鈥 given that some pills are new to the market or not yet available. And while studies indicated OxyContin, specifically, is harder to abuse, all of the drugs may shift people to other forms of opioids, notably heroin or fentanyl. (Silverman, 8/8)

As opioid addiction reaches epidemic proportions in American communities, investors are getting hooked on a U.K. company trying to wean them off. Indivior Plc makes Suboxone Film, a prescription medicine to treat dependence on illegal or prescription opioids, a class of drugs including heroin that act on the nervous system to聽relieve pain. Patients place the small, rectangular piece of film containing an active ingredient known as buprenorphine under their tongue or inside their cheek once a day to reduce cravings and suppress withdrawal symptoms. (Wiggins, 8/8)

In Prince George's County, Md., every first responder carries naloxone, the drug that can reverse an opioid overdose. "We carry it in our first-in bags," says Bryan Spies, the county's battalion chief in charge of emergency services. "So whenever we arrive at a patient's side, it's in the bag, along with things like glucose, aspirin and oxygen." (Kodjak, 8/8)

And outlets report on news from the crisis out of the states聽鈥

A call by Republican Gov. John Kasich for scientific breakthroughs to help solve the opioid crisis is drawing interest from dozens of groups with ideas including remote controlled medication dispensers, monitoring devices for addicts, mobile apps and pain-relieving massage gloves. The state has received project ideas from 44 hospitals, universities and various medical device, software and pharmaceutical developers that plan to apply for up to $12 million in competitive research-and-development grants. The grant money is being combined with $8 million for an Ohio Opioid Technology Challenge, a competition similar to one spearheaded by the NFL to address concussions. (8/8)

The epidemic of drug overdose deaths has hit home for the mayor of Nashville, Tenn. Her 22-year-old son, Max Barry, died last month of an overdose near Denver. And for the first time since tragedy struck her family, Mayor Megan Barry spoke publicly Monday to call on families to have frank and difficult conversations about addiction. (Gonzalez, 8/8)

While communities across the country deal with dramatic increases in illegal opioid use, statistics in Johnson County suggest rates of death and addiction closer to home are relatively more stable. Court filings involving opioid offenses have remained relatively flat in recent years, and illegal use has decreased for hydrocodone and oxycodone, two of the most popular opiates, according to a report from public health and crime experts presented to the Johnson County Commission in June. Heroin use remains steady. (Martin, 8/8)

Somewhere in a U.S. city, a small nonprofit organization has been hosting a secret site where users can inject drugs under the supervision of trained staff who provide clean needles and guard against overdoses, researchers said Tuesday. The site, which is illegal under federal law, has been operating for three years, according to a paper published in the American Journal of Preventive Medicine. It is part of the 鈥渉arm reduction鈥 strategy adopted by 98 facilities in 10 other countries where supervised injection sites operate legally. (Bernstein, 8/8)

Bellevue banned safe-injection sites for heroin users Monday although none has been proposed for King County鈥檚 second-largest city and it鈥檚 highly unlikely one would be. The controversial sites endorsed by Seattle Mayor Ed Murray and King County Executive Dow Constantine appear to have stalled, even as they ripple through local politics. (Young, 8/8)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Today, August 4
  • Monday, August 3
  • Friday, July 31
  • Thursday, July 30
  • Wednesday, July 29
  • Tuesday, July 28
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • 吃瓜不打烊
  • Republish Our Content
  • Contact Us

Follow Us

  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

漏 2026 KFF